Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir vs. Valganciclovir for CMV Prophylaxis in Kidney Transplant
NCT06034925Phase 4Completed
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of maribavir in cytomegalovirus infection (CMV) (2 arms), sponsored by Medical University of South Carolina. Primary endpoints: Incidence of Clinically Significant Leukopenia at 1 year and Incidence of CMV Infection at 1 year. Started Nov 2023; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06034925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034925.